University of Alabama at Birmingham

O'Neal Comprehensive Cancer Center

Birmingham, AL

Sorting 2 by

Accepting patients

CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more
  • CAR T Cell
  • CELMoD
  • GPRC5D
  • Phase 1

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1
1 hidden based on your filters. Show All